Growth Metrics

Gilead Sciences (GILD) Shareholder's Equity Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 3.94%
Dec 31, 2025 2.29%
Sep 30, 2025 0.76%
Jun 30, 2025 -1.04%
Mar 31, 2025 -1.42%
Dec 31, 2024 -2.96%
Sep 30, 2024 -5.03%
Jun 30, 2024 -2.63%
Mar 31, 2024 -2.73%
Dec 31, 2023 7.68%
Sep 30, 2023 8.38%
Jun 30, 2023 5.15%
Mar 31, 2023 -1.90%
Dec 31, 2022 -2.17%
Sep 30, 2022 0.51%
Jun 30, 2022 -3.86%
Mar 31, 2022 -3.40%
Dec 31, 2021 -0.73%
Sep 30, 2021 -2.28%
Jun 30, 2021 -3.21%
Mar 31, 2021 -2.80%
Dec 31, 2020 -3.85%
Sep 30, 2020 -11.07%
Jun 30, 2020 -7.73%
Mar 31, 2020 2.76%
Dec 31, 2019 5.37%
Sep 30, 2019 7.12%
Jun 30, 2019 12.18%
Mar 31, 2019 16.37%
Dec 31, 2018 4.06%
Sep 30, 2018 9.73%
Jun 30, 2018 9.32%
Mar 31, 2018 6.33%
Dec 31, 2017 9.03%
Sep 30, 2017 21.47%
Jun 30, 2017 12.01%
Mar 31, 2017 15.15%
Dec 31, 2016 18.13%
Sep 30, 2016 15.73%
Jun 30, 2016 13.26%
Mar 31, 2016 10.49%
Dec 31, 2015 26.05%
Sep 30, 2015 26.49%
Jun 30, 2015 27.62%
Mar 31, 2015 32.93%
Dec 31, 2014 32.07%
Sep 30, 2014 30.53%
Jun 30, 2014 39.54%
Mar 31, 2014 29.42%
Dec 31, 2013 24.26%
Sep 30, 2013 24.01%
Mar 31, 2013 11.47%
Dec 31, 2012 13.63%
Sep 30, 2012 15.07%
Jun 30, 2012 14.62%